INTRODUCTION:The aim of this study is to evaluate the distribution of the most common comorbid conditions associated with chronic temporomandibular disorders, and the Pharmacological agents which play an integral role in the overall management of temporomandibular joint disorders.
MATERIAL AND METHODS: A total of 23 articles are included in this comprehensive review of the relevant studies on common comorbid conditions related to temporomandibular disorders. This review provides summarized clinical and online platform based analyses focused on five most common comorbid conditions and its relevant pharmacological therapy.
RESULTS AND CONCLUSION: The majority of the studies show that comorbid conditions may include fibromyalgia, systemic myofascial pain and chronic fatigue syndrome, chronic headaches, migraine, heart arrhythmias, endometriosis, interstitial cystitis, irritable bowel syndrome, low back pain, sleep disorders - insomnia, autoimmune diseases, sleep apnea, noises and irritation in the ear, vulvodynia and mental disorders.The top comorbid conditions reported from people with TMJ syndrome, regardless of status are: anxiety, depression, insomnia, fatigue and pain.
Aggarwal VR, Lovell K, Peters S, et al. Psychosocial interventions for the management of chronic orofacial pain. Cochrane Database Syst Rev. 2011; (11): CD008456.
De Leeuw R, Klasser GD; American Academy of Orofacial Pain. Orofacial Pain: Guidelines for Assessment, Diagnosis, and Management. 5th ed. Chicago, Ill.: Quintessence Publ.; 2013.
DeNucci DJ, Sobiski C, Dionne RA. Triazolam improves sleep but fails to alter pain in TMD patients. J Orofac Pain. 1998; 12(2): 116-123.
Ekberg EC, Kopp S, Akerman S. Diclofenac sodium as an alternative treatment of temporomandibular joint pain. Acta Odontol Scand. 1996; 54(3): 154-159.
Gonçalves DA, Camparis CM, Speciali JG, et al. Temporomandibular disorders are differentially associated with headache diagnoses: a controlled study. Clin J Pain. 2011; 27(7): 611-615.
Grajales F, Clifford D, Loupos P et al. Social Networking Sites and the Continuously Learning Health System Institute of Medicine, Jan 23, 2014, http://www.iom.edu; https://www.openresearchexchange.com
Herman CR, Schiffman EL, Look JO, et al. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofac Pain. 2002; 16(1): 64-70.
Hersh EV, Balasubramaniam R, Pinto A. Pharmacologic management of temporomandibular disorders. Oral Maxillofac Surg Clin North Am. 2008; 20(2): 197-210.
Hoffmann RG, Kotchen JM, Kotchen TA, et al. Temporomandibular disorders and associated clinical comorbidities. Clin J Pain. 2011; 27(3): 268-274.
Indresano A, Alpha C. Nonsurgical management of temporomandibular joint disorders. In: Fonseca RJ, Marciani RD, Turvey TA, eds. Oral and Maxillofacial Surgery. 2nd ed. St. Louis, Mo.: Saunders/Elsevier; 2009: 881-897.
Kimos P, Biggs C, Mah J, et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain. 2007; 127(1-2): 151-160.
Kindler S, Samietz S, Houshmand M, et al. Depressive and anxiety symptoms as risk factors for temporomandibular joint pain: a prospective cohort study in the general population. J Pain. 2012; 13(12): 1188-1197.
Lim PF, Smith S, Bhalang K, et al. Development of temporomandibular disorders is associated with greater bodily pain experience. Clin J Pain. 2010; 26(2): 116-120.
List T, Axelsson S, Leijon G. Pharmacologic interventions in the treatment of temporomandibular disorders, atypical facial pain, and burning mouth syndrome. A qualitative systematic review. J Orofac Pain. 2003; 17(4): 301-310.
Machado E, Bonotto D, Cunali PA. Intra-articular injections with corticosteroids and sodium hyaluronate for treating temporomandibular joint disorders: a systematic review. Dental Press J Orthod. 2013; 18(5): 128-133.
Maixner W, Diatchenko L, Dubner R, et al. Orofacial pain prospective evaluation and risk assessment study-the OPPERA study. J Pain. 2011; 12(11 suppl): T4-T11.e1-2.
Martin WJ, Perez RS, Tuinzing DB, et al. Efficacy of antidepressants on orofacial pain: a systematic review. Int J Oral Maxillofac Surg. 2012; 41(12): 1532-1539.
Miloro M, Peterson LJ. Peterson`s Principles of Oral and Maxillofacial Surgery. 3rd ed. Shelton, Conn.: People`s Medical Pub House; 2012.
Mujakperuo HR, Watson M, Morrison R, et al. Pharmacological interventions for pain in patients with temporomandibular disorders. Cochrane Database Syst Rev. 2010; (10): CD004715.
Okeson JP, de Leeuw R. Differential diagnosis of temporomandibular disorders and other orofacial pain disorders. Dent Clin North Am. 2011; 55(1): 105-120.
Rizzatti-Barbosa CM, Nogueira MT, de Andrade ED, et al. Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders. Cranio. 2003; 21(3): 221-225.
Roldan OV, Maglione H, Carreira R, et al. Piroxicam, diazepam and placebo in the treatment of temporomandibular joint dysfunction. Double blind study [in Spanish]. Rev Asoc Odontol Argent. 1990; 78(2): 83-85.
Scrivani SJ, Keith DA, Kaban LB. Temporomandibular disorders. N Engl J Med. 2008; 359(25): 2693-2705.
Senye M, Mir CF, Morton S, et al. Topical nonsteroidal anti-inflammatory medications for treatment of temporomandibular joint degenerative pain: a systematic review. J Orofac Pain. 2012; 26(1): 26-32.
Shi Z, Guo C, Awad M. Hyaluronate for temporomandibular joint disorders. Cochrane Database Syst Rev. 2003; (1): CD002970.
Singer E, Dionne R. A controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain. J Orofac Pain. 1997; 11(2): 139-146.
Ta LE, Dionne RA. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. Pain. 2004; 111(1-2): 13-21.
Email this article (Login required) 
